Finland· FI-REL-REL28856
Rhesonativ
A anti-d (rh) immunoglobulin product containing human anti-d immunoglobulin, registered in Finland by Octapharma Ab. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Anti-d (rh) immunoglobulin is registered in 11 of 19 countries.
Countries holding a registration under ATC J06BB01 (anti-d (rh) immunoglobulin), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Anti-d (rh) immunoglobulin · ATC J06BB01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Human anti-D immunoglobulin
- Manufacturer
- Octapharma Ab
- Country
- Finland (FI)
- ATC code
- J06BB01
- ATC class
- Anti-D (rh) immunoglobulin
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Anti-d (rh) immunoglobulin in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAnti-D (RHO) immunoglobulin 1,250units/1ml solution for injection pre-filled syringesBaxter Healthcare Ltd
- United StatesHYPERRHOGRIFOLS USA, LLC
- NetherlandsRhesonativ 625 IE/ml, oplossing voor injectieOctapharma GmbH
- PolandGamma anty-D 150Synthaverse S.A.
- BelgiumImmunorho 300 µg/2 mlKedrion
- CzechiaIGAMADInstituto Grifols, S.A., Barcelona
- SwedenRhesonativ 625 IE/ml Injektionsvätska, lösningOctapharma AB
- ItalyIGAMAD*1 fiala IM 1.500 UI + 1 fiala solv 2 mlINSTITUTO GRIFOLS S.A.
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Rhesonativ, Rhophylac
- Belgium · Immunorho, Rhophylac
- Bulgaria · Резонатив
- Cyprus · Rhesonativ, Rhophylac
- Czechia · Igamad, Rhesonativ
- Germany · Rhesonativ, Rhophylac
- Denmark · Rhesonativ, Rhophylac
- Estonia · Rhesonativ
- Spain · Igamad, Rhophylac
- France · Rhesonativ, Rhophylac
- United Kingdom (Northern Ireland) · D-Gam, Rhophylac
- Greece · Rhophylac
- Hungary · Rhesonativ, Rhophylac
- Ireland · Rhophylac
- Iceland · Rhesonativ, Rhophylac
- Italy · Igamad, Immunorho
- Lithuania · Rhesonativ
- Luxembourg · Rhesonativ, Rhophylac
- Latvia · Rhesonativ
- Malta · Rhesonativ, Rhophylac
- Netherlands · Rhesonativ, Rhophylac
- Norway · Rhesonativ, Rhophylac
- Poland · Gamma Anty-D, Rhesonativ
- Portugal · Rhesonativ, Rhophylac
- Romania · Rhesonativ, Rhophylac
- Sweden · Rhesonativ, Rhophylac
- Slovenia · Rhesonativ, Rhophylac
- Slovakia · Igamad, Rhesonativ
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/76c12b1c-9b78-4a96-9bd3-d91e3a77dc87 GET /v1/drugs/76c12b1c-9b78-4a96-9bd3-d91e3a77dc87?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos",
"route": "Ihon alle",
"ddd_unit": null,
"strength": "625 IU/ml",
"atc_label": "anti-D-immunoglobuliini",
"ma_number": "23715",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL28856",
"authorised_at": "2008-02-22"
}See everything about anti-d (rh) immunoglobulin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.